AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04210492 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 45 Gray (Gy) regimen
Description: Deescalated 3-fraction stereotactic body radiotherapy regimen to 45 Gy in 3 fractions.
Study NCT02245867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
Description: The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
Study NCT00091962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation; Treatment recommendations
Description: Counseling program
Study NCT00091962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Description: Recommendations to patients' PCP for medication to treat depression
Study NCT00091962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Physicians' Usual care
Study NCT01102920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural strategies to promote physical activity and weight loss
Description: 8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician.
Study NCT01102920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP-treatment as usual (during nights)
Study NCT02333812 — intervention group
Intervention type: OTHER
Intervention: Stroboscopic nasopharyngeal laryngoscopy
Study NCT02360852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250
Description: A4250 once daily
Study NCT01409824 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: CDSS
Description: Clinical Decision Support System
Study NCT01697059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin + Amoxicillin
Study NCT02820441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zopiclone
Study NCT02820441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01544348 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
Study NCT01544348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
Study NCT01544348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 5 mg Subcutaneous
Description: A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
Study NCT01544348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 15 mg Subcutaneous
Description: A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
Study NCT01544348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 60 mg Subcutaneous
Description: A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
Study NCT01544348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 150 mg Subcutaneous
Description: A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
Study NCT01544348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 300 mg Subcutaneous
Description: A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
Study NCT01544348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4212 300 mg Intravenous
Description: A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
Study NCT02294617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Cigarette
Description: Subject will use electronic cigarette for 3 days.
Study NCT00659841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 200µg Ciclesonide versus placebo
Study NCT00659841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01229241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: local anesthetic
Description: postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml
Study NCT03689868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality headset with calming scenery
Study NCT00617838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal gluten introduction
Description: Optimization of gluten introduction by nutritional counselling
Study NCT00764946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: raltegravir
Description: 400 mg tablets taken twice daily. Total treatment period is 48 weeks.
Study NCT03388086 — intervention group
Intervention type: DRUG
Intervention: Injection of Onabotulinum toxin
Description: multiple injections of Onabotulinum toxin into the detrusor muscle
Study NCT03675113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity aerobic exercise
Description: Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department.
Study NCT03552627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Medical Oxygen
Study NCT03552627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Medical Oxygen
Study NCT03675113 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Deep breathing exercises combinated with arm movements
Study NCT02588157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Direct laryngoscopy
Study NCT02588157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Glidescope videolaryngoscope
Study NCT02588157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC X-Blade
Description: McGrath MAC X-Blade videolaryngoscope
Study NCT01677871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2HRZE/4HR
Description: Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
Study NCT01677871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2HRLE/4HR
Description: Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
Study NCT01677871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9HLE
Description: Isoniazid+ Levofloxacin+ Ethambutol for 9 months
Study NCT01677871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9RLE
Description: Rifampicin + Levofloxacin+ Ethambutol for 9 months
Study NCT02778984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuadraLite masks
Description: The intervention is identical in the two group
Study NCT02778984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard mask
Study NCT01052883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\]
Study NCT01052883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 \[Treatment B\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\]
Study NCT01052883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment D\], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 \[Treatment C\]
Study NCT01052883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV commercial formulation/ DRV new formulation/ rtv 100mg tab
Description: DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment A\], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 \[Treatment B\]
Study NCT00004227 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Study NCT00004227 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional surgery
Study NCT00004227 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT00004227 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Study NCT00004227 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT04068948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study NCT04068948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study NCT04068948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyzine
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study NCT04068948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study NCT04068948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
Study NCT03359369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: level of serum cholesterol and triglyceride
Description: other
Study NCT04570618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded AlgoDx Sepsis Prediction Algorithm
Description: When applicable, a sepsis prediction alert is displayed in the AlgoDx Medical Device Software.
Study NCT04570618 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blinded AlgoDx Sepsis Prediction Algorithm
Description: Standard of Care, i.e. no sepsis prediction alert.
Study NCT02459561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier TM Gastrointestinal Liner
Description: If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
Study NCT02459561 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Medical Care
Description: If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
Study NCT03063606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: CBT specialist treatment
Study NCT03063606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB Medication (on-going from acute treatment)
Description: Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
Study NCT03063606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NB Medication (on-going from acute treatment)
Description: Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
Study NCT02664519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forearm exercise training
Description: Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
Study NCT00712478 — intervention group
Intervention type: DRUG
Intervention: insulin
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT03877003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
Study NCT02461199 — intervention group
Intervention type: BIOLOGICAL
Intervention: Fecal microbiota transplantation
Description: Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
Study NCT03938831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
Study NCT03938831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl-based PCA infusion
Description: Fentanyl-based PCA infusion
Study NCT03938831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl-based PCA infusion
Description: Fentanyl-based PCA infusion
Study NCT00965289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab infusion on day 1 dose: 375mg/m²
Study NCT01892371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT01892371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC
Study NCT01892371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Given PO
Study NCT02294617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotrol Inhaler
Description: Subjects will use the Nicotrol Inhaler for 3 days.
Study NCT01598870 — intervention group
Intervention type: OTHER
Intervention: Diagnostic tests
Description: Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
Study NCT03675256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immediate Gardasil 9, delayed MenVeo vaccine
Description: Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
Study NCT03675256 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: immediate MenVeo vaccine, delayed Gardasil 9
Description: Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
Study NCT03675256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immediate Cervarix, delayed MenVeo vaccine
Description: Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
Study NCT03399604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIQ861 Inhaled Treprostinil
Description: LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Study NCT00921050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine sodium
Description: Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
Study NCT00921050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: excipient without levothyroxine (placebo)
Description: Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
Study NCT03606291 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: isotoxic hypofractionation
Description: the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
Study NCT02835144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIQAAM_therapy
Description: The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
Study NCT02835144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: This intervention is a psychoeducation module pertaining to substance use disorders.
Study NCT04283188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy
Description: Participants will be provided with the option to continue treatment with their study therapist. For those who elect to continue with DBT sessions, they will discuss frequency of sessions with their therapist, in addition to selecting type of sessions (individual and/or family skills). Participants who elect not to continue with DBT sessions at the time of enrollment will retain the option of being able to request additional sessions at any point during the 12-month study. Irrespective of participation in additional DBT sessions, all participants will be asked to complete follow-up interviews and questionnaires.
Study NCT00192543 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet of fish and fruit
Description: fish and fruit in specified quantities
Study NCT00192543 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: fruit and fish
Description: no drugs
Study NCT00192543 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet only
Description: Fish and fruit
Study NCT00192543 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: regular diet
Description: no change in regular diet
Study NCT00537537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telbivudine
Study NCT00077493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BL22 immunotoxin
Description: BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
Study NCT00077493 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: antibody-drug conjugate therapy
Description: CD22 antibody, RFB4 on day 7
Study NCT03464526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orvepitant
Description: Tablet, once daily, oral
Study NCT03590704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitaltape® bandage
Description: The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
Study NCT03384225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Study NCT03384225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Study NCT03384225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT03384225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Study NCT03384225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT03464526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily, oral